Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


Objective: The objective of this review is to determine whether ivabradine therapy can improve the quality of life in cardiovascular disease patients.

Study Design: The studies included in this review are one randomized control study and two double blind randomized control studies from 2008, 2010, and 2012.

Data Source: The three studies in this review were obtained by performing a PubMed search using the keywords “ivabradine” and random control trial.” All articles were published in English and in peer-reviewed journals.

Outcomes Measured: The three studies ascertained whether there was a decrease in hospitalization events within coronary artery disease and heart failure patients, if there was a subjective increase in the quality of life in heart failure patients, and whether there was an improvement in NYHA heart failure classification after ivabradine treatment.

Results: Patients with a resting heart rate of 70 beats per minute or greater who were treated with ivabradine demonstrated a statistically significant reduction in hospital admissions for myocardial infarctions (HR=0.64; 95% CI 0.49–0.84; p=0.001). This is a 36% reduction in myocardial infarctions. Heart failure patients treated with ivabradine were found to have a significantly lower risk of suffering a hospitalization event for worsening heart failure than the placebo group (HR=0.75; 95% CI 0.65-0.87; p

Conclusions: Based on the systematic reviews of the three randomized controlled trials, one can conclusively say that Corlanor (ivabradine) can improve the quality of life in cardiovascular disease patients. All three studies demonstrated statistically significant changes compared to control/placebo groups. These studies also demonstrate that ivabradine is efficacious and is well tolerated in terms of being safe for human use.